| 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.Clin Cancer Res | PMID 34158360PMC9401485 | 2021-Oct-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study.Am J Hematol | PMID 34161631无 PMCID | 2021-Oct-01 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.Clin Cancer Res | PMID 34301751PMC9662911 | 2021-Oct-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.J Clin Oncol | PMID 34343033PMC8478403 | 2021-Oct-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial.JAMA Oncol | PMID 34351356PMC8343504 | 2021-Oct-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.J Clin Oncol | PMID 34357781PMC8478386 | 2021-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.J Clin Oncol | PMID 34379442无 PMCID | 2021-Oct-01 | 0.95 | The trial is an oncology randomized Phase III with a primary cognitive function endpoint and OS as a secondary time-to-event endpoint. However, the intervention is a radiation technique comparison (prophylactic cranial irradiation with or without hippocampal avoidance), not a drug-containing intervention. Therefore, it does not meet the drug-intervention criterion for inclusion. | 待处理 |
| Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.JAMA Oncol | PMID 34383006PMC8531992 | 2021-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.JAMA Dermatol | PMID 34406366PMC8374743 | 2021-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial.JAMA Oncol | PMID 34436523PMC8391772 | 2021-Oct-01 | 0.95 | The study is a Phase III randomized oncology trial with a drug intervention, but the primary endpoint is a cardiac safety/efficacy measure (subclinical myocardial impairment), not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the eligibility criterion for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Short-term Outcomes of Robotic Gastrectomy vs Laparoscopic Gastrectomy for Patients With Gastric Cancer: A Randomized Clinical Trial.JAMA Surg | PMID 34468701PMC8411361 | 2021-Oct-01 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.Cornea | PMID 34481407PMC8423142 | 2021-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).Blood Cancer J | PMID 34599139PMC8486817 | 2021-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study.Eur J Dermatol | PMID 34789441无 PMCID | 2021-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.J Manag Care Spec Pharm | PMID 34595948PMC10391115 | 2021-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done".Ophthalmology | PMID 31668888无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.Ther Apher Dial | PMID 33200512PMC8451884 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study.Ther Apher Dial | PMID 33340238PMC8451904 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.Ophthalmol Retina | PMID 33373715PMC8233398 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.Ann Surg Oncol | PMID 33641012PMC7914039 | 2021-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes.J Diabetes Investig | PMID 33751849PMC8504901 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.Br J Dermatol | PMID 33763874PMC8518877 | 2021-Oct | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.Cancer Res Treat | PMID 33781053PMC8524025 | 2021-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.Ophthalmology | PMID 33798654无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.Cephalalgia | PMID 33939497PMC8504413 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.Am J Ophthalmol | PMID 33945820无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The HELENA study: Hexvix®-TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study.World J Urol | PMID 34002265PMC8521513 | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases.Surgery | PMID 34030885无 PMCID | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.J Urol | PMID 34039013无 PMCID | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.Clin Pharmacol Ther | PMID 34048027PMC8449801 | 2021-Oct | 0.45 | While the record describes an oncology, human, randomized, Phase III drug trial, the abstract does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. It is a pharmacogenomic subgroup analysis of SNP-treatment interactions, not a primary efficacy result report. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort. | 待处理 |
| Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.Clin Lymphoma Myeloma Leuk | PMID 34059488PMC8528179 | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.J Eur Acad Dermatol Venereol | PMID 34076919无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.Lancet Infect Dis | PMID 34081923无 PMCID | 2021-Oct | 0.85 | The study is a phase 3 randomized trial in oncology (HPV vaccines to prevent cancer) with a drug intervention, but the primary endpoint is immunogenicity (antibody persistence) and correlation with efficacy against persistent infections, not a standard time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier or HR analysis. | 待处理 |
| Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial.J Bone Miner Res | PMID 34101900PMC8597097 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Effect of Pirfenidone on the Prescription of Antibiotics and Antitussive Drugs in Patients With Idiopathic Pulmonary Fibrosis: A Post Hoc Exploratory Analysis of Phase III Clinical Trial.Chest | PMID 34102142无 PMCID | 2021-Oct | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).Oncologist | PMID 34105207PMC8488800 | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.Diabetes Obes Metab | PMID 34121308无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms.JCO Oncol Pract | PMID 34125586PMC9810143 | 2021-Oct | 0.95 | The study is a randomized Phase III trial with a primary endpoint (patient-reported Likert scale) but lacks a drug intervention (it tests consent forms) and does not have a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). | 待处理 |
| Acute and Chronic Placental Abnormalities in a Multicenter Cohort of Newborn Infants with Hypoxic-Ischemic Encephalopathy.J Pediatr | PMID 34144032PMC13010375 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).Gastroenterology | PMID 34144047无 PMCID | 2021-Oct | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.Diabetes Obes Metab | PMID 34169625无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial.Epilepsy Res | PMID 34246118无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.Future Oncol | PMID 34254530无 PMCID | 2021-Oct | 0.45 | The record describes the protocol/design of a Phase III randomized oncology trial and an early biomarker study within it. It does not report the primary or secondary time-to-event efficacy outcomes (survival, progression, etc.) required for inclusion in a Kaplan-Meier digitization cohort. | 待处理 |
| Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.J Thromb Haemost | PMID 34255420无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.Leukemia | PMID 34274940PMC8744070 | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.Expert Rev Anticancer Ther | PMID 34281470无 PMCID | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.Br J Haematol | PMID 34331348PMC9292894 | 2021-Oct | 0.95 | The report describes a randomized, placebo-controlled Phase III trial of a drug (fedratinib) in oncology (myelofibrosis), but the primary efficacy endpoints are response rates (spleen volume response, symptom response), which are categorical, not time-to-event. There is no explicit mention of overall survival, progression-free survival, or any other time-to-event endpoint in the provided abstract. | 待处理 |
| IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial.Pediatr Neurol | PMID 34339951无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires.CPT Pharmacometrics Syst Pharmacol | PMID 34346168PMC8520748 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.Gynecol Oncol | PMID 34353615PMC9555119 | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |